Literatur
- 1
Asuncion M, Calvo R M, San Millan J L. et al .
A prospective study of the prevalence of the polycystic ovary syndrome in unselected
Caucasian women from Spain.
J Clin Endocrinol Metab.
2000;
85
2434-2438
- 2
Basaria S, Muller D C. et al .
Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation
therpy.
Cancer.
2006;
106
581-586
- 3
Basin S, Enzlin P, Coriello A, Basson R.
Sexual dysfunction in men and women with endocrine disorders.
Lancet.
2007;
369
597-611
- 4
Bhasin S, Cunningham G R, Hayes F J. et al .
Testosteron therapy in adult men with androgen deficiency syndromes: an Endocrin Society
Clinical Practice Guideline.
J Clin Endocrinol Metabol.
2006;
91
1995-2000
- 5
Brettenthaler N. et al .
Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism,
and ovulatory dysfunction in women with polycystic ovary syndrome.
J Clin Endocrinol Metab.
2004;
89
3835-3840
- 6
Dunaif A.
Insulin resistance and the polycystic ovary syndrome: mechanism and implications for
pathogenesis.
Endocr Rev.
1997;
18
774-800
- 7
Hahn S, Haselhorst U, Quadbeck B. et al. .
Decreased soluble receptor levels in women with polycystic overy syndrome.
Eur J Endocrinol.
2006;
154
287-294
- 8
Heutling D, Schulz H. et al .
Asymmetric dimethylarginine and metabolic parameters in women with polycystic ovary
syndrome before and after metformin treatment.
J Clin Endocrinol Metab;.
, in Revision.
- 9
Jayagopal V, Kilpatrick E S, Holding S. et al .
Orlistat is as beneficial as Metformin in the Treatment of Poycystic Ovarian Syndrome.
J Clin Endocrinol Metab.
2005;
90
729-733
- 10
Kapoor D, Aldred H, Clark S. et al .
Clinical and biochemical assessment of hypogonadism in men with type 2 dianetes: correlations
with bioavailable testosterone and visceral adiposity.
Diab Care.
2007;
30
911-907
- 11
Kapoor D, Goodwin E, Channer K S, Jones T H.
Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral
adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes.
Eur J Endocrinol.
2006;
154
899-906
- 12
Kauffmann I M, Vermeulen A K.
The decline of androgen levels in elderly men and ist clinical and therapeutic implications.
Endocr Rev.
2005;
26
833-876
- 13
Kupelian V, Page S T, Araujo A B. et al .
Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency
are associated with the development of the metabolic syndrome in non-obese men.
J Clin Endocrinol Metab.
2006;
91
843-850
- 14
Laaksonen D E. et al .
Testosteron and sex hormone-binding globulin predict the metabolic syndrome and diabetes
in middle aged men.
Diab Care.
2004;
27
1036-1041
- 15
Legro R S. et al .
Insulin resistance in the sisters of women with polycystic ovary syndrome: association
with hyperandrogenämia rather than menstrual irregularity.
J Clin Endocrinol Metab.
2002;
87
2128-2133
- 16
Legro R S, Zaino R J, Memers L M. et al .
The effects of metformin and rosiglitazone, alone and in combination, on the ovary
and endometrium in polycystic ovary syndrome.
Am J Obstet Gynecol.
2007;
196
402.e1-10
- 17
Lewandowski K C. et al .
Adiponectin and Resistin Serum Levels In Women With Polycystic Ovary Syndrome During
Oral Glucose Tolerance Test (OGTT): A Significant Reciprocal Correlation Between Adiponectin
And Resistin Independent Of Insulin Resistance Indices.
Mol Genet Metab.
2005;
85
61-69
- 18
Lord J M, Flight I CH, Norman R J.
Metformin in polycystic ovary syndrome.
BMJ.
2003;
327
951-953
- 19
Luque-Ramirez M, Alvarez-Blesco F. et al .
Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects
on classic metabolic cardiovascular risk factors in women with the polycystic ovary
syndrome.
J Clin Endocrinol Metab.
2007;
, ; epub ahead of print
- 20
Muller M, Grobbee D E, den Tonkelar I. et al .
Endogenous sex hormones and metabolic syndrome in aging men.
J Clin Endocrinol Metab.
2005;
90
2618-2623
- 21
Orio F, Matarese G, Di Biase S. et al .
Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic
ovary syndrome.
J Clin Endocrinol Metab.
2003;
88
5887-5892
- 22
Orio F, Palomba S, Spinelli L. et al .
The cardiovascular risk of young women with polycystic ovary syndrome: an observational,
analytical, prospective case-control study.
J Clin Endocrinol Metab.
2004;
89
3696-3701
- 23
Palomba S, Falbo A, Russo T. et al .
Insulin sensitivity after medformin suspension in normal-weight woman with polycystic
ovary syndrome.
J Clin Endocrinol Metab.
2007;
, ; epub ahead of print
- 24
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group .
Revised 2003 consensus on diagnostic criteria and long-term health risk related to
polycystic ovary syndrome.
Fertil Steril.
2004;
81
19-25
- 25
Seow K M. et al .
Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance.
Human Reproduction.
2004;
19
48-53
- 26
Shores M M, Matsumoto A M, Sloan K L, Kirlahan D R.
Low serum testosteron and mole veterans.
Arch Int Med.
2006;
166
1660-1665
- 27
Talbott E O. et al .
Evidence for an association between metabolic cardiovascular syndrome and coronary
and aortic calcification among women with polycystic ovary syndrome.
J Clin Endocrinol Metab.
2004;
89
5454-5461
- 28
Weyer C. et al .
Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin
resistance and hyperinsulinemia.
J Clin Endocrinol Metab.
2001;
86
1930-1935
- 29
Zitzmann M, Faber S, Nieschlag E.
Association of specific symptoms and metabolic risks with serum testosterone in older
men.
J Clin Endocrinol Metab.
2006;
91
4335-4343
Prof. Hendrik Lehnert, MD FRCP
Chair of Medicine, Warwick Medical School, University Hospital of Coventry Warwickshire
Clifford Bridge Road
Coventry CV2 2DX UK
Email: h.lehnert@warwick.ac.uk
